Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iobenguane I-131 + vorinostat
- Development stage
- Phase 2
- Lead developer
- Jubilant Radiopharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
iobenguane I-131 + vorinostat is an investigational combination therapy for recurrent or progressive high-risk neuroblastoma. It combines *iobenguane I-131* (also known as 131I-MIBG), a radiopharmaceutical that delivers targeted radiation to neuroblastoma cells, with *vorinostat*, a small molecule inhibitor of histone deacetylases (HDAC). Iobenguane I-131 specifically accumulates in neuroendocrine tumor cells due to its structural similarity to norepinephrine, leading to selective cell death from radioactive decay. Vorinostat sensitizes cancer cells to radiation by altering chromatin structure and making DNA more susceptible to damage. This synergy aims to improve outcomes in neuroblastoma patients resistant or unresponsive to prior therapies[1][2][3][4][5][6].
- Other names
- I-131 MIBG + vorinostat131I-MIBG + vorinostat
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)NET (Norepinephrine Transporter)DNA
Beyond the preview
Go deeper on iobenguane I-131 + vorinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iobenguane I-131 + vorinostat.